共 50 条
Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use
被引:204
|作者:
Baggish, Aaron L.
[1
,2
]
Weiner, Rory B.
[1
,2
]
Kanayama, Gen
[3
,4
,5
]
Hudson, James I.
[3
,4
,5
]
Lu, Michael T.
[6
,7
]
Hoffmann, Udo
[6
,7
]
Pope, Harrison G., Jr.
[3
,4
,5
]
机构:
[1] Massachusetts Gen Hosp, Div Cardiol, Cardiovasc Performance Program, Boston, MA 02114 USA
[2] Harvard Med Sch, Dept Med, Boston, MA USA
[3] McLean Hosp, Biol Psychiat Lab, 115 Mill St, Belmont, MA 02178 USA
[4] McLean Hosp, Psychiat Epidemiol Res Program, 115 Mill St, Belmont, MA 02178 USA
[5] Harvard Med Sch, Dept Psychiat, Boston, MA USA
[6] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA
[7] Harvard Med Sch, Dept Radiol, Boston, MA 02114 USA
关键词:
anabolic-androgenic steroids;
atherosclerosis;
cardiology;
cardiomyopathy;
diastolic dysfunction;
men;
RISK-FACTORS;
VENTRICULAR HYPERTROPHY;
MYOCARDIAL-INFARCTION;
TISSUE DOPPLER;
SOCIETY;
WEIGHTLIFTERS;
TESTOSTERONE;
CONSEQUENCES;
DYSFUNCTION;
PREVALENCE;
D O I:
10.1161/CIRCULATIONAHA.116.026945
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
BACKGROUND: Millions of individuals have used illicit anabolic-androgenic steroids (AAS), but the long-term cardiovascular associations of these drugs remain incompletely understood. METHODS: Using a cross-sectional cohort design, we recruited 140 experienced male weightlifters 34 to 54 years of age, comprising 86 men reporting >= 2 years of cumulative lifetime AAS use and 54 nonusing men. Using transthoracic echocardiography and coronary computed tomography angiography, we assessed 3 primary outcome measures: left ventricular (LV) systolic function (left ventricular ejection fraction), LV diastolic function (early relaxation velocity), and coronary atherosclerosis (coronary artery plaque volume). RESULTS: Compared with nonusers, AAS users demonstrated relatively reduced LV systolic function (mean +/- SD left ventricular ejection fraction = 52 +/- 11% versus 63 +/- 8%; P < 0.001) and diastolic function (early relaxation velocity = 9.3 +/- 2.4 cm/second versus 11.1 +/- 2.0 cm/second; P < 0.001). Users currently taking AAS at the time of evaluation (N=58) showed significantly reduced LV systolic (left ventricular ejection fraction = 49 +/- 10% versus 58 +/- 10%; P < 0.001) and diastolic function (early relaxation velocity = 8.9 +/- 2.4 cm/second versus 10.1 +/- 2.4 cm/second; P=0.035) compared with users currently off-drug (N=28). In addition, AAS users demonstrated higher coronary artery plaque volume than nonusers (median [interquartile range] 3 [0, 174] mL(3) versus 0 [0, 69] mL(3);P=0.012). Lifetime AAS dose was strongly associated with coronary atherosclerotic burden (increase [95% confidence interval] in rank of plaque volume for each 10-year increase in cumulative duration of AAS use: 0.60 SD units [0.16-1.03 SD units]; P=0.008). CONCLUSIONS: Long-term AAS use appears to be associated with myocardial dysfunction and accelerated coronary atherosclerosis. These forms of AAS-associated adverse cardiovascular phenotypes may represent a previously underrecognized public-health problem.
引用
收藏
页码:1991 / +
页数:26
相关论文